Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors

Lancet

Volumn 363, Issue 9413, 2004, Pages 938-947

  Liu, Shuwen ^a   Xiao, Gengfu ^b   Chen, Yibang ^c   He, Yuxian ^a   Niu, Jinkui ^a   Escalante, Carlos R ^c   Xiong, Huabao ^c   Farmar, James ^a   Debnath, Asim K ^a   Tien, Po ^b   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b WUHAN UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINO ACID DERIVATIVE; BUFFER; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PHOSPHATE; VIRUS FUSION PROTEIN;

ALPHA HELIX; ARTICLE; CIRCULAR DICHROISM; COMPUTER ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; SARS CORONAVIRUS; SEDIMENTATION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SURFACE PLASMON RESONANCE; VIRUS INFECTION;

EID: 12144287276     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15788-7     Document Type: Article

References (50)

1. WHO. Summary of probable SARS cases with onset of illness from Nov 1, 2002, to July 31, 2003. www.who.int (accessed Dec 19, 2003).
2. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 348:2003;1953-1966.
3. Drosten C., Gunther S., Preiser W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 348:2003;1967-1976.
4. Peiris J.S., Lai S.T., Poon L.L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 361:2003;1319-1325.
5. Marra M.A., Jones S.J.M., Astell C.R., et al. The genome sequence of the SARS-associated coronavirus. Science. 300:2003;1399-1404.
6. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:2003;1394-1399.
7. Li W.H., Moore M.J., Vasilieva N.Y., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426:2003;450-454.
8. Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 302:2003;276-278.
9. Cavanagh D. The coronavirus surface glycoprotein. Siddell S.G. The coronaviridae. 1995;73-114 Plenum Press, New York.
10. Lai M.M., Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res. 48:1997;1-100.
11. Gallagher T.M. A role for naturally occurring variation of the murine coronavirus spike protein in stabilizing association with the cellular receptor. J Virol. 71:1997;3129-3137.
12. Holmes K.V. SARS-associated coronavirus. N Engl J Med. 348:2003;1948-1951.
13. Gallaher W.R., Ball J.M., Garry R.F., et al. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 5:1989;431-440.
14. Jiang S., Lin K., Strick N., et al. HIV-1 inhibition by a peptide. Nature. 365:1993;113.
15. Wild C., Oas T., McDanal C., et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA. 89:1992;10537-10541.
16. Wild C.T., Shugars D.C., Greenwell T.K., et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA. 91:1994;9770-9774.
17. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol. 2:1995;1075-1082.
18. Chan D.C., Fass D., Berger J.M., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
19. Weissenhorn W., Dessen A., Harrison S.C., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-428.
20. Jiang S., Zhao Q., Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des. 8:2002;563-580.
21. Blacklow S.C., Lu M., Kim P.S. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry. 34:1995;14955-14962.
22. Lombardi S., Massi C., Indino E., et al. Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Virology. 220:1996;274-284.
23. Watanabe S., Takada A., Watanabe T., et al. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol. 74:2000;10194-10201.
24. Yu M., Wang E., Liu Y., et al. Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus. J Gen Virol. 83:2002;623-629.
25. Wang E., Sun X., Qian Y., et al. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. Biochem Biophys Res Commun. 302:2003;469-475.
26. Qin E., Zhu Q., Yu M., et al. A complete sequence and comparative analysis of a SARS-associated virus (isolate BJ01). Chin Sci Bull. 48:2003;941-948.
27. Zhao Q., Ernst J.T., Hamilton A.D., et al. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses. 18:2002;989-997.
28. Jones D.K., Badii R., Rosell F.I., et al. Bacterial expression and spectroscopic characterization of soybean leghaemoglobin a. Biochem J. 330:1998;983-988.
29. Johnson M.L., Correia J.J., Yphantis D.A., et al. Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys J. 36:1981;575-588.
30. Liu S., Zhao Q., Jiang S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide. 24:2003;1303-1313.
31. Wolf E., Kim P.S., Berger B. MultiCoil: a program for predicting two- and three-stranded coiled coils. Protein Sci. 6:1997;1179-1189.
32. Thompson J.D., Gibson T.J., Plewniak F., et al. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:1997;4876-4882.
33. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 234:1993;779-815.
34. Laskowski R.A., Moss D.S., Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J Mol Biol. 231:1993;1049-1067.
35. Vakser I.A., Matar O.G., Lam C.F. A systematic study of low-resolution recognition in protein-protein complexes. Proc Natl Acad Sci USA. 96:1999;8477-8482.
36. Katchalski-Katzir E., Shariv I., Eisenstein M., et al. Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. Proc Natl Acad Sci USA. 89:1992;2195-2199.
37. Rost B. PHD: predicting one-dimensional protein structure by profile-based neural networks. Methods Enzymol. 266:1996;525-539.
38. Krueger D.K., Kelly S.M., Lewicki D.N., et al. Variations in disparate regions of the murine coronavirus spike protein impact the initiation of membrane fusion. J Virol. 75:2001;2792-2802.
39. White J.M. Membrane fusion. Science. 258:1992;917-924.
40. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
41. Dwyer J.J., Hasan A., Wilson K.L., et al. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry. 42:2003;4945-4953.
42. Luo Z., Matthews A.M., Weiss S.R. Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion. J Virol. 73:1999;8152-8159.
43. Bosch B.J., van der Z.R., de Haan C.A., et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 77:2003;8801-8811.
44. Jiang S., Lin K., Strick N., et al. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem Biophys Res Commun. 195:1993;533-538.
45. Yao Q., Compans R.W. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology. 223:1996;103-112.
46. Reeves J.D., Gallo S.A., Ahmad N., et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 99:2002;16249-16254.
47. Jiang S., Lin K. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 gp41 sequence. Peptide Res. 8:1995;345-348.
48. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA. 95:1998;15613-15617.
49. Jiang S., Lin K., Zhang L., et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods. 80:1999;85-96.
50. Debnath A.K., Radigan L., Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem. 42:1999;3203-3209.